<DOC>
	<DOCNO>NCT00553683</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cyclophosphamide , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray type radiation kill tumor cell . Specialized radiation therapy delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . Poly ICLC may stop growth liver cancer block blood flow tumor . Giving drug directly arteries around tumor may kill tumor cell . Giving cyclophosphamide radiation therapy together poly ICLC may effective treatment liver cancer . PURPOSE : This phase I/II trial study side effect give cyclophosphamide , radiation therapy , poly ICLC together see well work treat patient unresectable , recurrent , primary , metastatic liver cancer .</brief_summary>
	<brief_title>Cyclophosphamide , Radiation Therapy , Poly ICLC Treating Patients With Unresectable , Recurrent , Primary , Metastatic Liver Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To study safety effectiveness strategy establish robust anticancer immunologic body defenses use low-dose radiation therapy liver cancer order increase tumor targetability ; inject body defense activator , polyinosinic-polycytidylic acid polylysine carboxymethylcellulose ( poly ICLC , hiltonol , oncovir ) , around cancer activate sentinel dendritic cell alarm body defense ; shut local production factor suppress body 's natural anticancer defense starve cancer blood supply within liver . OUTLINE : Patients receive low-dose oral cyclophosphamide daily day 1-21 undergo 3-dimensional conformal radiotherapy day 21-23 . On day 24 , patient undergo intra- peri-tumoral polyinosinic-polycytidylic acid polylysine carboxymethylcellulose ( poly ICLC ) injection directly tumor follow trans-hepatic artery embolization designate tumor . Patients receive poly ICLC subcutaneously day 26 , 35 , 37 , 42 , 44 , 49 , 51 . Treatment repeat every 57 day 3 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year every 6 month thereafter .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Poly ICLC</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Radiologically histologically confirm hepatocellular carcinoma Stage III IV primary disease Recurrent , unresectable , metastatic disease meeting follow criterion : Pancreatic cancer underwent prior surgical resection progress recurrent metastatic disease liver Gastric , colon , breast , ovarian cancer melanoma metastatic disease liver Primary recurrent disease surgically resect leave patient diseasefree Radiologically measurable disease Ineligible liver transplantation accord University San Francisco list criterion : Single lesion &gt; 6.5 cm Three tumor &gt; 4.5 cm Cumulative tumor diameter &gt; 8 cm PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % ANC ≥ 1,500/mm³ Platelets ≥ 75,000/mm³ Creatinine ≤ 1.7 mg/dL Total bilirubin ≤ 1.5 mg/dL AST ALT ≤ 3 time upper limit normal INR &lt; 1.5 LVEF ≥ 50 % Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious concurrent infection medical illness would render protocol treatment unsafe LVEF ≥ 50 % PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent steroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>liver metastasis</keyword>
</DOC>